<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81983">
  <stage>Registered</stage>
  <submitdate>24/04/2007</submitdate>
  <approvaldate>1/05/2007</approvaldate>
  <actrnumber>ACTRN12607000229471</actrnumber>
  <trial_identification>
    <studytitle>The effects of a Marinova seaweed extract on osteoarthritis</studytitle>
    <scientifictitle>Participant: Individuals with osteoarthritis
Intervention: Seaweed extract
Outcome: Comprehensive Osteoarthritis test
Comparator:Dose comparison</scientifictitle>
    <utrn />
    <trialacronym>N/A</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Seaweed extract derived from Marine macroalgae, dose complarison study.  Five participants will take 100grams twice a day and five will take 1gram twice a day.  The tablets will be self-administered by the participants each morning before breakfast and each evening.  The study will continue for 12 weeks after the initial baseline visit, measurement points are at baseline, week 1, week 6 and week 12.</interventions>
    <comparator>No comparator.</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>COAT (Comprehensive Osteoarthritis Test) - This instrument consists of four items measured on 100mm visual analogue scale (VAS) response scales: 
 - joint pain
 - stiffness
 - difficulties with physical activities
 - overall symptoms</outcome>
      <timepoint>Measured daily for 12 weeks.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Paracetamol usage</outcome>
      <timepoint>Participants will record paracetamol usage on a daily basis in a study diary, logged daily for 12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>X-ray and clinical evidence of osteoarthritis of the kneesIn good general healthAdequate venous accessParticipants willing to discontinue their current OA (osteoarthritis) treatment for the duration of the study.  This includes treatment with intra-articular injections, corticosteroids, NSAIDs (non steroidal anti inflammatory drug), non-prescription therapies, chondroprotective agents, occlusive dressings, physiotherapy, or orthopaedic technical measuresParticipants of childbearing age who agree to continue using birth control measures for the duration of the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>A history of trauma associated with the affected jointRheumatoid or other inflammatory joint conditionsGoutUse of corticosteroids (intra-articular or systematic) within 4 weeks prior to baseline and throughout the studyUse of anti-inflammatory agents or anti-arthritic complementary medicines 3 weeks prior to baseline and for the duration of the studyLiver function tests greater than 3 times the upper limit of normal at baselineHistory of alcohol or substance abuseFemale participants who are lactating, pregnant or planning to become pregnantParticipants who have participated in another clinical trial in the last 30 daysParticipants unwilling to comply with the study protocolAny other condition, which in the opinion of the investigators could compromise the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Computerised sequence generation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>2/07/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Marinova Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Marinova Pty Ltd</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a pilot study designed to gather data pertinent to the development of a large scale clinical trial,  The study is an open label trial to be conducted over 12 weeks in otherwise healthy individuals.  The study will compare baseline Comprehensive Osteoarthritis Test (COAT) measurements with end of study outcomes</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>NatMed-Research Department fo Natural and Complementary Medicine Southern Cross University</ethicname>
      <ethicaddress>Lismore NSW</ethicaddress>
      <ethicapprovaldate>16/04/2007</ethicapprovaldate>
      <hrec>ECN-07-37</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Joan O'Connor</name>
      <address>NatMed-Research
Department of Natural and Complementary Medicine
Southern Cross University
Military Road
Lismore NSW</address>
      <phone>02 66 20 3649</phone>
      <fax>02 66 20 3307</fax>
      <email>joconnor@scu.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Joan O'Connor</name>
      <address>NatMed-Research
Department of Natural and Complementary Medicine
Southern Cross University
Military Road
Lismore NSW</address>
      <phone>02 66 20 3649</phone>
      <fax>02 66 20 3307</fax>
      <email>joconnor@scu.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>